Literature DB >> 25912691

Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.

Rômulo Dias Novaes1, Eliziária C Santos, Marli C Cupertino, Daniel S S Bastos, Jerusa M Oliveira, Thaís V Carvalho, Mariana M Neves, Leandro L Oliveira, André Talvani.   

Abstract

This study used a murine model of Chagas disease to investigate the isolated and combined impact of Trypanosoma cruzi infection and benznidazole (BZ) therapy on liver structure and function. Male C57BL/6 mice were challenged with T. cruzi and BZ for 15 days. Serum levels of cytokines and hepatic enzymes, liver oxidative stress, morphology, collagen, and glycogen content were monitored. Separately, T. cruzi infection and BZ treatment resulted in a pro-oxidant status and hepatic reactive damage. Concurrently, both T. cruzi infection and BZ treatment induced upregulation of antioxidant enzymes and pathological reorganization of the liver parenchyma and stroma. T. cruzi infection increased serum levels of Th1 cytokines, which were reduced by BZ in both infected and non-infected animals. BZ also induced functional organ damage, increasing serum levels of liver enzymes. When combined, T. cruzi infection and BZ therapy elicited intense hepatic reactive damage that was not compensated by antioxidant enzymatic reaction, subsequently culminating in more severe morphofunctional hepatic injury. Taken together, these findings indicate that during specific treatment of Chagas disease, hepatic pathology may be a result of an interaction between BZ metabolism and specific mechanisms activated during the natural course of T. cruzi infection, rather than an isolated toxic effect of BZ on liver structure and function.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25912691     DOI: 10.1007/s00436-015-4488-x

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  40 in total

1.  Drug-induced liver injury: mechanisms and test systems.

Authors:  D M Bissell; G J Gores; D L Laskin; J H Hoofnagle
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

2.  Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi.

Authors:  Z BRENER
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1962 Nov-Dec       Impact factor: 1.846

3.  Plasma total antioxidant capacity, lipid peroxidation, and erythrocyte antioxidant enzyme activities in patients with rheumatoid arthritis and osteoarthritis.

Authors:  Sezgin Sarban; Abdurrahim Kocyigit; Mithat Yazar; Ugur E Isikan
Journal:  Clin Biochem       Date:  2005-09-16       Impact factor: 3.281

4.  Trypanosoma cruzi-mediated IFN-gamma-inducible nitric oxide output in macrophages is regulated by iNOS mRNA stability.

Authors:  Marc Bergeron; Martin Olivier
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  Trypanosoma cruzi infection induces morphological reorganization of the myocardium parenchyma and stroma, and modifies the mechanical properties of atrial and ventricular cardiomyocytes in rats.

Authors:  Rômulo D Novaes; Arlete R Penitente; Reggiani V Gonçalves; André Talvani; Maria C G Peluzio; Clóvis A Neves; Antônio J Natali; Izabel R S C Maldonado
Journal:  Cardiovasc Pathol       Date:  2013-03-28       Impact factor: 2.185

Review 6.  Chagas disease: Present status of pathogenic mechanisms and chemotherapy.

Authors:  Juan Diego Maya; Myriam Orellana; Jorge Ferreira; Ulrike Kemmerling; Rodrigo López-Muñoz; Antonio Morello
Journal:  Biol Res       Date:  2010-11-30       Impact factor: 5.612

Review 7.  The current state of serum biomarkers of hepatotoxicity.

Authors:  Josef Ozer; Marcia Ratner; Martin Shaw; Wendy Bailey; Shelli Schomaker
Journal:  Toxicology       Date:  2007-12-05       Impact factor: 4.221

8.  A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections.

Authors:  A López-De León; M Rojkind
Journal:  J Histochem Cytochem       Date:  1985-08       Impact factor: 2.479

9.  Fexinidazole: a potential new drug candidate for Chagas disease.

Authors:  Maria Terezinha Bahia; Isabel Mayer de Andrade; Tassiane Assíria Fontes Martins; Álvaro Fernando da Silva do Nascimento; Lívia de Figueiredo Diniz; Ivo Santana Caldas; André Talvani; Bernadette Bourdin Trunz; Els Torreele; Isabela Ribeiro
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

10.  [Not Available].

Authors:  Shivali Gupta; Jian-Jun Wen; Nisha Jain Garg
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-06-14
View more
  6 in total

1.  Benefits of Ascorbic Acid in Association with Low-Dose Benznidazole in Treatment of Chagas Disease.

Authors:  Maiara Voltarelli Providello; Zumira Aparecida Carneiro; Gisele Bulhões Portapilla; Gabriel Tavares do Vale; Ricardo Souza Camargo; Carlos Renato Tirapelli; Sérgio de Albuquerque
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

2.  The trypanocidal benznidazole promotes adaptive response to oxidative injury: Involvement of the nuclear factor-erythroid 2-related factor-2 (Nrf2) and multidrug resistance associated protein 2 (MRP2).

Authors:  Juan Pablo Rigalli; Virginia Gabriela Perdomo; Nadia Ciriaci; Daniel Eleazar Antonio Francés; María Teresa Ronco; Amy Michele Bataille; Carolina Inés Ghanem; María Laura Ruiz; José Enrique Manautou; Viviana Alicia Catania
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-12       Impact factor: 4.219

3.  Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.

Authors:  Rômulo Dias Novaes; Marcus Vinicius Pessoa Sartini; João Paulo Ferreira Rodrigues; Reggiani Vilela Gonçalves; Eliziária Cardoso Santos; Raquel Lopes Martins Souza; Ivo Santana Caldas
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

4.  Relevance of Trypanothione Reductase Inhibitors on Trypanosoma cruzi Infection: A Systematic Review, Meta-Analysis, and In Silico Integrated Approach.

Authors:  Andréa Aparecida Santos Mendonça; Camila Morais Coelho; Marcia Paranho Veloso; Ivo Santana Caldas; Reggiani Vilela Gonçalves; Antônio Lucio Teixeira; Aline Silva de Miranda; Rômulo Dias Novaes
Journal:  Oxid Med Cell Longev       Date:  2018-10-24       Impact factor: 6.543

5.  Hepatic changes by benznidazole in a specific treatment for Chagas disease.

Authors:  Tycha Bianca Sabaini Pavan; Jamiro Wanderley da Silva; Luiz Cláudio Martins; Sandra Cecília Botelho Costa; Eros Antônio de Almeida
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

6.  Purinergic Antagonist Suramin Aggravates Myocarditis and Increases Mortality by Enhancing Parasitism, Inflammation, and Reactive Tissue Damage in Trypanosoma cruzi-Infected Mice.

Authors:  Rômulo D Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Andréa A S Mendonça; Eduardo de Almeida Marques-da-Silva; Sílvia A Cardoso; Juliana L R Fietto; Leandro L Oliveira
Journal:  Oxid Med Cell Longev       Date:  2018-09-30       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.